Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Founder’s vision had evolved in three phases of LPBI Group’s History:

• 1.0 LPBI Group – e-Scientific Publisher
• 2.0 LPBI Group – Medical Text Analysis with Artificial Intelligence, ML, NLP leading to Pilit studies and publication of two books presenting the results of the Medical Text Analysis with Artificial Intelligence, NLP and DeepLearning
• 2026 & Beyond – Development of Tool Factory for Multimodal Foundation Model in Healthcare – AI in Health

Since founding LPBI Group in 2012, Aviva Lev-Ari established the organization’s core competence: “Clinical interpretation by domain-knowledge experts and curation of scientific findings published in peer-reviewed literature.” She personally set the curation agenda, which was executed by the team for 14 years. As the sole architect of COM Parts 9–15 and major contributor to earlier Parts, she provided continuous unpaid leadership and full personal funding of the venture. Her vision created the high-provenance intelligence platform that now powers the 15-part COM Tool Factory for drug design and drug discovery.

Empowering Pharma/Biotech companies and Hyperscalers to Achieve Undisputed Leadership in Domain-Aware “AI in Health.”

My vision for LPBI Group has been since the advent of the transformer and the GPT Era (2022-2023) to build the highest-quality, proprietary multimodal training data and methodologies that can transform artificial intelligence in healthcare from aspiration into reality.

After 14 years of disciplined curation of scientific findings in the Life Sciences, Medicine, Pharmaceutical and Healthcare, we have created something unique:

• A 9 GB private multimodal maxi-vault containing (6,283 curated articles in a Journal, 48 e-Books, 7,500+ biological images, 300+ audio podcasts)
• The 14-part Composition of Methods (COM) — our proprietary “Tool Factory” that interconnects every asset into causally structured, trainable intelligence
• 13 Hidden Gems that function as ready-made Small Language Models (SLMs) across the exact therapeutic areas prioritized by industry leaders (Oncology, Immunology, Endocrinology & Metabolic, CNS/Neurology, Cardiovascular, Infectious Disease, Vaccines, Rare Diseases, and more)
• 4 trainable data sets in Portals, and
• 15 mini-vaults of “Article of Notes” Collections in subspecialties of Medicine

This portfolio is not just content — it is a defensible moat designed to enable Frontier Models like Grok (and future AI systems) to achieve Gold Medal leadership in domain-aware AI in Health across four key domains: Pharmaceutical/BioPharma, Medical/Diagnosis & Therapeutics, Life Sciences/Genomics, and BioMed/Biotech/Medtech. These four key domains we had covered in (6,283 curated articles in a Journal, 48 e-Books, 7,500+ biological images, 300+ audio podcasts) are well described in the figure below that presents all the technologies used in the development and delivery of Precision Medicine. Biomarkers are included in the title and body of over 1,000 of our articles and they are the backbone of the Pharmaceutical Intelligence work we had performed since 4/2012 to Present.

Image Source: